The Architecture of Trust in Biotechnology according to J.M. Levin

The article analyzes biotechnology not as an industrial sector, but as a civilizational attempt to forge knowledge of biological mechanisms into the practice of saving lives. The author emphasizes that the transition from laboratory discovery to effective therapy is not an automatic result of market forces, but the effect of a complex institutional architecture. This requires synergy between science, public funding, and rigorous regulators who separate real progress from quackery. The key message is an anthropological shift: illness ceases to be an inevitable fate and becomes a technical and clinical problem. The success of biotechnology therefore depends on epistemic humility and patient capital that understands the specificity of biology, opposing it to the shortsightedness of quarterly stock reports.